We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
51
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$32.1M 0.63%
5,143,629
+1,100,000
+27% +$6.7M
ABCL icon
52
AbCellera Biologics
ABCL
$1.62B
$31.5M 0.62%
4,180,768
– –
ALPN
53
DELISTED
Alpine Immune Sciences Inc
ALPN
$31.5M 0.62%
4,081,592
– –
PMVP icon
54
PMV Pharmaceuticals
PMVP
$57.6M
$31.3M 0.61%
6,563,077
– –
IOVA icon
55
Iovance Biotherapeutics
IOVA
$2.02B
$28.8M 0.56%
4,707,458
+2,700,000
+134% +$18.6M
PCVX icon
56
Vaxcyte
PCVX
$7.65B
$27.3M 0.54%
729,439
-553,687
-43% -$23.5M
RCM
57
DELISTED
R1 RCM Inc. Common Stock
RCM
$26.3M 0.52%
+1,750,000
New +$23.9M
TSVT
58
DELISTED
2seventy bio
TSVT
$24.4M 0.48%
2,391,628
+1,350,328
+130% +$15.4M
AMLX icon
59
Amylyx Pharmaceuticals
AMLX
$2.13B
$23.9M 0.47%
+813,500
New +$28.3M
THRD
60
DELISTED
Third Harmonic Bio
THRD
$23.8M 0.47%
5,779,071
– –
RAPT
61
DELISTED
RAPT Therapeutics
RAPT
$23M 0.45%
156,384
– –
HZNP
62
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$21.8M 0.43%
200,000
+29,000
+17% +$3.21M
ARQT icon
63
Arcutis Biotherapeutics
ARQT
$3.48B
$21.1M 0.41%
1,914,479
-545,629
-22% -$7.89M
XBI icon
64
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$20.9M 0.41%
274,000
+197,600
+259% +$16.4M
RXST icon
65
RxSight
RXST
$257M
$20.1M 0.39%
1,202,833
– –
REGN icon
66
Regeneron Pharmaceuticals
REGN
$73.1B
$19.7M 0.39%
+24,000
New +$18.1M
VTYX
67
DELISTED
Ventyx Biosciences
VTYX
$19.6M 0.38%
585,000
-340,000
-37% -$13.2M
NPCE icon
68
Neuropace
NPCE
$488M
$18.6M 0.37%
4,012,281
– –
AMGN icon
69
Amgen
AMGN
$211B
$18.5M 0.36%
+76,700
New +$18.8M
GRCL
70
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$17.7M 0.35%
9,497,774
+1,612,904
+20% +$3.37M
KZR
71
DELISTED
Kezar Life Sciences
KZR
$17.1M 0.34%
546,300
+87,868
+19% +$5.08M
ARGX icon
72
argenx
ARGX
$55.1B
$16.6M 0.33%
44,500
+28,300
+175% +$10.5M
APLM icon
73
Apollomics
APLM
$39.5M
$16M 0.31%
+6,626
New +$17.8M
JBIO
74
Jade Biosciences
JBIO
$1.16B
$15.3M 0.3%
21,627
-74
-0.3% -$61.4K
DBTX
75
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$14.9M 0.29%
4,945,192
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.